Ionis Pharmaceuticals Inc. (IONS)’s Financial Results Comparing With Stemline Therapeutics Inc. (NASDAQ:STML)

As Biotechnology businesses, Ionis Pharmaceuticals Inc. (NASDAQ:IONS) and Stemline Therapeutics Inc. (NASDAQ:STML), are affected by compare. This especially applies to their risk, institutional ownership, analyst recommendations, profitability, dividends, earnings and valuation.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Ionis Pharmaceuticals Inc. 599.67M 17.87 276.87M 0.51 137.95
Stemline Therapeutics Inc. N/A 1057.71 80.14M -3.00 0.00

Table 1 shows gross revenue, earnings per share and valuation of the two companies.


Table 2 provides Ionis Pharmaceuticals Inc. and Stemline Therapeutics Inc.’s return on assets, return on equity and net margins.

Net Margins Return on Equity Return on Assets
Ionis Pharmaceuticals Inc. 46.17% -31.1% -8.7%
Stemline Therapeutics Inc. 0.00% -114.5% -90.2%

Volatility and Risk

Ionis Pharmaceuticals Inc.’s 2.39 beta indicates that its volatility is 139.00% more volatile than that of S&P 500. Stemline Therapeutics Inc.’s 12.00% more volatile than S&P 500 volatility due to the stock’s 1.12 beta.


The Current Ratio of Ionis Pharmaceuticals Inc. is 8 while its Quick Ratio stands at 8. The Current Ratio of rival Stemline Therapeutics Inc. is 4.6 and its Quick Ratio is has 4.6. Ionis Pharmaceuticals Inc. is better equipped to clear short and long-term obligations than Stemline Therapeutics Inc.

Analyst Recommendations

The Recommendations and Ratings for Ionis Pharmaceuticals Inc. and Stemline Therapeutics Inc. are featured in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Ionis Pharmaceuticals Inc. 0 0 1 3.00
Stemline Therapeutics Inc. 0 0 4 3.00

$82 is Ionis Pharmaceuticals Inc.’s consensus target price while its potential upside is 5.89%. Competitively the consensus target price of Stemline Therapeutics Inc. is $29, which is potential 115.29% upside. The information presented earlier suggests that Stemline Therapeutics Inc. looks more robust than Ionis Pharmaceuticals Inc. as far as analyst opinion.

Insider & Institutional Ownership

Roughly 89.1% of Ionis Pharmaceuticals Inc. shares are owned by institutional investors while 51.3% of Stemline Therapeutics Inc. are owned by institutional investors. Ionis Pharmaceuticals Inc.’s share owned by insiders are 0.2%. Comparatively, insiders own roughly 9.4% of Stemline Therapeutics Inc.’s shares.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Ionis Pharmaceuticals Inc. 14.3% 21.53% 21.62% 52.61% 33.45% 30.39%
Stemline Therapeutics Inc. -4.36% 3.16% 8.46% -31.27% -31.88% 20.11%

For the past year Ionis Pharmaceuticals Inc. was more bullish than Stemline Therapeutics Inc.


On 9 of the 11 factors Ionis Pharmaceuticals Inc. beats Stemline Therapeutics Inc.

Ionis Pharmaceuticals, Inc. engages in discovering and developing RNA-targeted therapeutics. The company markets SPINRAZA, an antisense drug for spinal muscular atrophy in pediatric and adult patients; and Kynamro an oligonucleotide inhibitor for use in patients with homozygous familial hypercholesterolemia to reduce low density lipoprotein-cholesterol, apolipoprotein B, total cholesterol, and non-high density lipoprotein-cholesterol, and as an adjunct to lipid lowering medications and diet. Its drugs in Phase III development include volanesorsen for the treatment of patients with familial chylomicronemia syndrome and familial partial lipodystrophy; and IONIS-TTRRx, an antisense drug to treat all forms of transthyretin amyloidosis. The company also develops IONIS-HTTRx, an antisense drug to treat patients with Huntington's disease; IONIS-SOD1Rx, an antisense drug to treat patients with an inherited form of amyotrophic lateral sclerosis; AKCEA-ANGPTL3-LRx, a LICA drug for treating multiple lipid disorders or mixed dyslipidemias; IONIS-PKKRx, an antisense drug that treats patients with hereditary angioedema; IONIS-FXIRx, an antisense drug for the treatment of thrombosis; AKCEA-APO(a)-LRx, a LICA drug that reduces apolipoprotein(a) in the liver to offer a direct approach for reducing lipoprotein(a); and AKCEA-APOCIII-LRx, an antisense drug for cardiometabolic disease. In addition, it develops IONIS-AR-2.5Rx, an antisense drug that treats patients with prostate cancer; IONIS-STAT3-2.5Rx, a cancer drug; AKCEA-ANGPTL3-LRx, a LICA drug to treat multiple lipid disorders; IONIS-GCGRRx, an antisense drug to treat patients with type 2 diabetes; and IONIS-DGAT2Rx, an antisense drug to treat patients with liver disease. The company was formerly known as Isis Pharmaceuticals, Inc. and changed its name to Ionis Pharmaceuticals, Inc. in December 2015. Ionis Pharmaceuticals, Inc. was founded in 1989 and is headquartered in Carlsbad, California.

Stemline Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovering, acquiring, developing, and commercialization of proprietary oncology therapeutics in the United States. The company develops SL-401, a targeted therapy directed to the interleukin-3 receptor (IL-3R), which is in Phase II clinical trial for patients with blastic plasmacytoid dendritic cell neoplasm, myeloproliferative neoplasms, and acute myeloid leukemia; and in Phase I clinical trial in combination with other agents for patients with relapsed/refractory multiple myeloma. It also develops SL-801, a novel oral small molecule reversible inhibitor of a tumor-promoting nuclear transport protein, which is in Phase I clinical trial for the treatment of solid and hematologic cancers; and SL-701, an immunotherapy that is in Phase II clinical trial to attack brain cancer. In addition, it develops SL-501, a next generation IL-3R-targeted therapy that is in preclinical development. Stemline Therapeutics, Inc. was founded in 2003 and is based in New York, New York.